Lynn Seely - 11 May 2026 Form 4 Insider Report for Lyell Immunopharma, Inc. (LYEL)

Reporting relationship: President and CEO, Director
Issuer ticker: LYEL
Reported as of: 11 May 2026
Net transaction value: -$7,337
SEC form: 4
Accepted by SEC: 15 Jun 2026, 18:37:17 UTC
Prior SEC filing: 12 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Mark Meltz, Attorney-in-Fact

Key filing fact

Lynn Seely filed Form 4 for Lyell Immunopharma, Inc. (LYEL) on 15 Jun 2026.

Key facts

This page summarizes Lynn Seely's Form 4 filing for Lyell Immunopharma, Inc. (LYEL).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 15 Jun 2026, 18:37.

Change

Previous filing in this sequence was filed on 12 Feb 2026.
Current net transaction value: -$7,337.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001327111 Primary reporting owner

Seely Lynn

Relationship: President and CEO, Director
Address: C/O LYELL IMMUNOPHARMA, INC., 201 HASKINS WAY, SOUTH SAN FRANCISCO
Signature: /s/ Mark Meltz, Attorney-in-Fact
Signature date: 15 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

LYEL transaction

Common Stock

Sale

Transaction value: $7,337
Shares: -388
Change %: -0.52%
Price: $18.91
Shares after: 73,878
Date: 11 May 2026
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.

Footnote F2

The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $18.91 to $19.15 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.